Related Experiment Video

Updated: Feb 22, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K

[Targeted treatment of renal cell carcinoma, treatment caused side-effects and side-effect management]

Krisztián Nagyiványi1, Lajos Géczi1

  • 1Kemoterápia C. és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet Budapest, Ráth György u. 7-9., 1122.

Orvosi Hetilap
|September 19, 2017
PubMed

Insights

Recent advances in targeted therapy and immunotherapy have transformed the treatment of advanced renal cell carcinoma (RCC), offering new hope for patients. This review covers current and emerging therapies, emphasizing side-effect management for kidney cancer patients.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Limited therapeutic options existed for advanced renal cell carcinoma (RCC) until recently.
  • Conventional chemotherapy and cytokine treatments showed limited efficacy in most RCC patients.
  • The landscape of RCC treatment has significantly changed since 2005.

Purpose of the Study:

  • To review current and emerging treatment modalities for unresectable and/or metastatic renal cell carcinoma.
  • To focus on therapy-induced side effects and their management.
  • To provide an updated overview of kidney cancer treatment strategies.

Main Methods:

  • Literature review of recent advancements in targeted therapy and immunotherapy for RCC.
  • Analysis of treatment efficacy and side effect profiles.
  • Synthesis of information on emerging therapies and management strategies.

Main Results:

  • Target-based therapies and immunotherapies have revolutionized RCC treatment.
  • These novel approaches offer improved outcomes compared to traditional methods.
  • Understanding and managing treatment-related side effects is crucial for patient care.

Conclusions:

  • Modern targeted and immune therapies represent a paradigm shift in advanced renal cell carcinoma management.
  • Effective side-effect management is essential for optimizing patient outcomes and quality of life.
  • Continued research into novel therapies and supportive care is vital for kidney cancer patients.
Keywords:
biomarkerekbiomarkerscélzott (targeted) kezelésekimmunotherapyimmunterápiamTOR-gátlókmammalian target of rapamycin inhibitorsmellékhatásokrenal cell carcinomaside-effectstargeted treatmentstirozinkináz-gátlóktyrosine kinase inhibitorsvascular endothelial growth factor inhibitorsvascularis endothelialis növekedési faktort gátlókvesesejtes carcinoma

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
503
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
291
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
591